TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31151199
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil supplementation (400 mg EPA and DHA per day)
Study: 31151199
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil supplementation (800 mg EPA + DHA per day)
Study: 17183729
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose simvastatin (80 mg)
Study: 10750576
Drug: Neridronate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate (50 mg iv every 2 months for a year)
Study: 9117754
Drug: 5% Amlexanox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Amlexanox oral paste
Study: 8362449
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) once weekly
Study: 8362449
Drug: Proguanil (PROG)
DrugBank: Proguanil (DB01131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proguanil (PROG) daily
Study: 8362449
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Chloroquine and Proguanil (CQ + PROG)
Study: 3095780
Drug: Total antibiotic
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total antibiotic decontamination (TAD) with gentamicin, vancomycin and colimycin
Study: 29492615
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral GR3027
Study: 29492615
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg oral GR3027
Study: 23035890
Drug: g-FOBT (guaiac-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: g-FOBT (guaiac-based fecal occult blood test)
Study: 18552672
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard microsurgical treatment)
Study: 8769206
Drug: Neoral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral therapy
Study: 1385658
Drug: Graded activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded activity program with a behavioral therapy approach (n = 51)
Study: 30272245
Drug: Active V1
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active V1 subcutaneous trigeminal nerve stimulation (sTNS) as adjuvant to medical therapy
Study: 20096909
Drug: Praneem polyherbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praneem polyherbal tablet
Study: 12476932
Drug: Prednisolone, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 20 mg twice daily
Study: 10330639
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of 0.5 mL lidocaine 1%
Study: 8955574
Drug: Injective immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injective immunotherapy
Study: 1836290
Drug: 10 mcg
Normalized name: D400, 10 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mcg recombinant DNA yeast-derived hepatitis B vaccine
Study: 1836290
Drug: 20 mcg
Normalized name: Caverject 20 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg recombinant DNA yeast-derived hepatitis B vaccine
Study: 1836290
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (10 mcg and 20 mcg)
Study: 7425396
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (11 patients receiving injections for the first time)
Study: 7425396
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (20 patients already receiving injections)
Study: 7425396
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (20 control patients who did not receive any injections)
Study: 31274231
Drug: E39 +
Normalized name: E39' vaccine
DrugBank: GALE-302 (DB17962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E39 + GM-CSF vaccine (1000 μg)
Study: 31274231
Drug: E39 +
Normalized name: E39' vaccine
DrugBank: GALE-302 (DB17962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E39 + GM-CSF vaccine (<1000 μg)
Study: 31274231
Drug: E39 +
Normalized name: E39' vaccine
DrugBank: GALE-302 (DB17962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E39 + GM-CSF vaccine (any dose)
Study: 28696286
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin treatment (24 International Units, twice daily for 4 weeks)
Study: 25282519
Drug: Placebo monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo monthly
Study: 2660519
Drug: Muroctasin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muroctasin (both doses)
Study: 29077862
Drug: ASP requiring
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP requiring re-authorization of restricted antibiotics on day 3
Study: 26747333
Drug: 24,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24,000 IU of vitamin D3 plus 300 μg of calcifediol
Study: 26415294
Drug: Kruarone 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kruarone 0.6 mg/kg
Study: 20920765
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg) + Budesonide (200 μg)
Study: 20920765
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 μg)
Study: 17015817
Drug: Ramelteon (16,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (16, 80, or 160 mg)
Study: 17015817
Drug: Triazolam (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25, 0.5, or 0.75 mg)
Study: 12821462
Drug: Gemifloxacin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin administered alone
Study: 12821462
Drug: Gemifloxacin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin administered simultaneously with calcium carbonate
Study: 12821462
Drug: Gemifloxacin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin administered 2 h before calcium carbonate
Study: 12821462
Drug: Gemifloxacin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin administered 2 h after calcium carbonate
Study: 10804490
Drug: Placement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of a subcutaneous closed suction drain
Study: 31518454
Drug: Triangular neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triangular neck implant (test)
Study: 31518454
Drug: Round neck
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round neck implant (control)
Study: 31518454
Drug: Both implants
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implants (triangular and round neck)
Study: 31518454
Drug: Triangular neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triangular neck implant
Study: 24587355
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg AMP at encoding and placebo at retrieval (condition AP)
Study: 2234715
Drug: Elective delivery
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective delivery 48 hours after administration of betamethasone (aggressive-management group)
Study: 736293
Drug: Atropine, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine, 0.4 mg
Study: 736293
Drug: Glycopyrrolate, 0.2
Normalized name: Glycopyrrolate, 0.2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate, 0.2 mg
Study: 736293
Drug: Saline solution,
Normalized name: Sterile Saline Solution, Contact Lens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution, 1 ml
Study: 736293
Drug: No anticholinergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticholinergic drug
Study: 24067488
Drug: Nurse-led algorithm-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led algorithm-based treatment
Study: 24067488
Drug: Gastroenterologist-led algorithm-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastroenterologist-led algorithm-based treatment
Study: 21424588
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula (5 L/min)
Study: 21424588
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask (5 L/min)
Study: 18344727
Drug: Venlafaxine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine monotherapy
Study: 18344727
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate monotherapy
Study: 15607840
Drug: Illicit use
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illicit use of prescription pain medication from peers
Study: 15607840
Drug: Illicit use
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illicit use of prescription pain medication from family members
Study: 15607840
Drug: Previous prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous prescription of pain medication
Study: 840556
Drug: Daily phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily phenobarbital
Study: 26123286
Drug: Ferric(III)carboxymaltose infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric(III)carboxymaltose infusion
Study: 26123286
Drug: Ferrofumarate (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrofumarate (oral iron supplementation)
Study: 21457153
Drug: Subcostal TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcostal TAP catheters with 1 mg.kg(‐1) bupivacaine 0.375% every 8 h
Study: 21457153
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine 0.125% and fentanyl 2 μg.ml(‐1)
Study: 19318435
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of large waist circumference and elevated glucose
Study: 11912568
Drug: Topiramate (512
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (512 mg/day)
Study: 8163132
Drug: Second-look endoscopy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-look endoscopy within the first 24 hours with repeated injection if a visible vessel was still identified
Study: 20458988
Drug: Frozen gel
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen gel pack applied to sternal incision dressing before DB & C exercises
Study: 20458988
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel pack
Study: 11549104
Drug: Theophylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (600 mg) alone
Study: 11549104
Drug: Tegaserod (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (6 mg) and Theophylline (600 mg)
Study: 11549104
Drug: Tegaserod (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (6 mg)
Study: 9928569
Drug: Infusional 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusional 5-FU 200 mg/m2 per day for up to 6 months in combination with 3-weekly bolus epirubicin (60 mg/m2) and cisplatin (60 mg/m2)
Study: 30431605
Drug: Modified quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified quadruple therapy (proton‐pump inhibitor bid, amoxicillin 1 g bid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid daily)
Study: 30431605
Drug: Bismuth‐containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth‐containing quadruple therapy (proton‐pump inhibitor bid, tetracycline 500 mg qid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid daily)
Study: 25305762
Drug: 25‐µg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐µg sublingual misoprostol with vaginal placebo
Study: 25305762
Drug: 50‐µg intravaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50‐µg intravaginal misoprostol with sublingual placebo
Study: 22449658
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (n=74, 3 g intravenous injection before the procedure and oral 1 g per day for 2 days after the procedure)
Study: 15667874
Drug: 2% rectal
Normalized name: Ana-Lex, 2%-2% rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% rectal lidocaine gel
Study: 15667874
Drug: Perianal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perianal injection of 1% lidocaine
Study: 15667874
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lidocaine gel)
Study: 11336160
Drug: Normal fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal fructose absorption
Study: 31077858
Drug: Antibacterials in
Normalized name: OTHER ANTIBACTERIALS in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterials in outpatient prescriptions at township health centers
Study: 31077858
Drug: Antibacterials in
Normalized name: OTHER ANTIBACTERIALS in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterials in outpatient prescriptions at community health service centers
Study: 23609776
Drug: Insoluble wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insoluble wheat bran fibre-containing breakfast cereal (5.4 g fibre, 3.5 g from wheat bran)
Study: 21606430
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus DTIC (10 mg/m2/min at 1800 mg/m2 followed by DTIC at 500 mg/m2 every 2 weeks)
Study: 21606430
Drug: DTIC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC alone (1200 mg/m2 every 3 weeks)
Study: 19194189
Drug: Low Hb
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Hb level (<12 g/dL)
Study: 16126256
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment with rtPA
Study: 16126256
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic treatment (Control)
Study: 15330958
Drug: 22‐G hollow
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22‐G hollow needle (group I)
Study: 15330958
Drug: 22‐G caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22‐G caudal block needle (group II)
Study: 11233236
Drug: Neoadjuvant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radiochemotherapy (40 Gy radiation, low-dose fraction cisplatin 7 mg/body/day for 5 days a week for 4 weeks, and 5-fluorouracil 350 mg/body/day for 28 days)
Study: 11233236
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (high-dose fraction cisplatin 70 mg/m2/day on day 1 and 5-fluorouracil 700 mg/m2/day on days 1-5)
Study: 9253574
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PGE1-induced hypotension and haemodilution (Group D)
Study: 8494421
Drug: St. Thomas'
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. Thomas' Hospital solution (STS)
Study: 29522355
Drug: NaNO3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaNO3 supplementation (1 g/day, n = 13)
Study: 27980499
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (6 mg∙kg‐1 body mass anhydrous caffeine)
Study: 25319951
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg 12 h before PCI, and a further 20 mg 2 h preprocedure)
Study: 22678167
Drug: Trimethoprim-sulfamethoxazole (DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (DS twice daily)
Study: 12602406
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and glucose-lowering sulphonylurea
Study: 30052328
Drug: Alicapistat 400-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicapistat 400- or 800-mg twice-daily doses
Study: 30052328
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg twice daily (active control)
Study: 30052328
Drug: Alicapistat (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicapistat (various doses)
Study: 19460767
Drug: ADX10059 250
Normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX10059 250 mg tds
Study: 19460767
Drug: ADX10059 50
Normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX10059 50 mg tds
Study: 17172351
Drug: docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 60 mg/m2 and cisplatin 50 mg/m2
Study: 17172351
Drug: paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 175 mg/m2 and cisplatin 50 mg/m2
Study: 7672876
Drug: Contractubex gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contractubex gel (10% onion extract, 50/U of sodium heparin per 1g of gel, 1% allantoin), applied topically for one year starting 26 days post-operation.
Study: 2919059
Drug: Chlorhexidine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.1% mouthrinses (rinsed four times daily)
Study: 22849770
Drug: ACT‐178882 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐178882 (single dose 30 mg in fed state)
Study: 22849770
Drug: ACT‐178882 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐178882 (multiple doses 30‐600 mg once daily for 14 days)
Study: 22849770
Drug: ACT‐178882 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐178882 (single doses 10‐1000 mg)
Study: 22849770
Drug: ACT‐178882 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐178882 (multiple doses)
Study: 21742303
Drug: Low-fluence photodynamic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluence photodynamic therapy (PDT)
Study: 24729079
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of ranibizumab
Study: 14695940
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term administration of a nutraceutical formulation based on coenzyme Q10, vitamin E, selenium, methionine, and phospholipids
Study: 10649623
Drug: Pnc conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pnc conjugate vaccine (1, 3, or 10 micrograms of PSs conjugated to diphtheria or tetanus toxoid)
Study: 10649623
Drug: Pnc conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pnc conjugate vaccine
Study: 8783392
Drug: Regular nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular nicotine cigarette (0.7 mg)
Study: 8783392
Drug: Denicotinised cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denicotinised cigarette (0.1 mg)
Study: 2937411
Drug: celiprolol hydrochloride
Normalized name: Celiprolol hydrochloride
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol hydrochloride (300 mg once daily for 4 weeks)
Study: 26232049
Drug: Intravenous IgG
Normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous IgG administered at replacement dosages
Study: 20556613
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (docetaxel with 150 mg single-dose oral casopitant)
Study: 18940393
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg/d) with pioglitazone (30 mg/d)
Study: 18940393
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/d) + Placebo
Study: 16801406
Drug: Telbivudine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 200 mg/day
Study: 16801406
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg/day
Study: 16801406
Drug: Telbivudine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine with lamivudine (100 mg/day)
Study: 16801406
Drug: Telbivudine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine with adefovir dipivoxil (10 mg/day)
Study: 12974995
Drug: Paroxetine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine augmentation
Study: 12974995
Drug: Paroxetine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (in patients with lithium levels <=0.8 mequiv./l)
Study: 12974995
Drug: Moclobemide monotherapy
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide monotherapy
Study: 10831173
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion of 3.3 mmol/kg lysine hydrochloride over 90 minutes
Study: 23174399
Drug: Ranibizumab monotherapy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monotherapy (control)
Study: 16575739
Drug: Posaconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (200 mg on day 1, followed by 100 mg/day for 13 days)
Study: 16575739
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg on day 1, followed by 100 mg/day for 13 days)
Study: 12676389
Drug: Prostaglandin E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E(2) tablets
Study: 9163863
Drug: CyA-ME (microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA-ME (microemulsion formulation)
Study: 9163863
Drug: CyA-GC (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA-GC (corn oil-based gel capsule)